Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/108753| Title: | Targeting the mevalonate and mammalian target of rapamycin pathways in breast cancer |
| Authors: | Petroni, Vanessa Fenech, Anthony G. Camilleri Podesta, Marie Therese Grech, Godfrey |
| Keywords: | Breast -- Cancer -- Treatment -- Malta mTOR associated protein, LST8 homolog Statins (Cardiovascular agents) Rapamycin Hydroxymethylglutaryl coenzyme A reductases |
| Issue Date: | 2015 |
| Publisher: | University of Malta. Medical School |
| Citation: | Petroni, V., Fenech, A.G., Camilleri Podesta, M.T., & Grech, G. (2015). Targeting the mevalonate and mammalian target of rapamycin pathways in breast cancer. IX Malta Medical School Conference abstract book, P16.06. |
| Abstract: | Introduction: Breast cancer is the commonest cause of cancer mortality in Maltese females. The availability of eukaryotic translation initiation factor 4E (eIF4E) is reduced by mammalian target of rapamycin (mTOR) inhibitors e.g. rapamycin and metformin. Expression of 3-hydroxy-3-methylglutarylcoenzynre A reductase (HMG-CoA reductase), the mevalonate pathway rate limiting enzyme, is regulated by eIF4E. Additionally statins e.g. simvastatin, are HMG-CoA reductase inhibitors. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/108753 |
| ISSN: | 18133339 |
| Appears in Collections: | Scholarly Works - FacM&SPat |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Targeting the mevalonate and mammalian target of rapamycin pathways in breast cancer 2015.pdf | 113.13 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.